These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 18321176)
1. Type 2 diabetes among women: clinical considerations for pharmacological management to achieve glycemic control and reduce cardiovascular risk. Levine JP J Womens Health (Larchmt); 2008 Mar; 17(2):249-60. PubMed ID: 18321176 [TBL] [Abstract][Full Text] [Related]
2. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes. Caballero AE J Diabetes Complications; 2009; 23(2):143-52. PubMed ID: 18413192 [TBL] [Abstract][Full Text] [Related]
3. [Tight glycemic control in the management of diabetic patients: what has changed since the '90s in the clinical approach?]. Fiorentino TV; Sesti G G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):13S-20S. PubMed ID: 25623546 [TBL] [Abstract][Full Text] [Related]
4. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes. Lebovitz HE Diabetes Care; 1999 Apr; 22 Suppl 3():C41-4. PubMed ID: 10189561 [TBL] [Abstract][Full Text] [Related]
5. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. Dailey G Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus. Cavender MA; Lincoff AM Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327 [TBL] [Abstract][Full Text] [Related]
7. Issues surrounding tight glycemic control in people with type 2 diabetes mellitus. Cerveny JD; Leder RD; Weart CW Ann Pharmacother; 1998 Sep; 32(9):896-905. PubMed ID: 9762378 [TBL] [Abstract][Full Text] [Related]
8. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé. Bajaj M; Jialal I Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292 [No Abstract] [Full Text] [Related]
9. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Tandon N; Ali MK; Narayan KM Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193 [TBL] [Abstract][Full Text] [Related]
10. [Postprandial hyperglycemia. Cardiovascular risks and new therapeutic strategies]. Sjöholm A Lakartidningen; 2001 Feb; 98(9):937-40. PubMed ID: 11292972 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs. Panicker GK; Karnad DR; Salvi V; Kothari S J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547 [TBL] [Abstract][Full Text] [Related]
12. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes. Weiss IA; Valiquette G; Schwarcz MD Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678 [TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease. Ragucci E; Zonszein J; Frishman WH Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986 [TBL] [Abstract][Full Text] [Related]
14. Achieving glycemic control: cornerstone in the treatment of patients with multiple metabolic risk factors. Spellman CW J Am Osteopath Assoc; 2009 May; 109(5 Suppl):S8-S13. PubMed ID: 19451256 [TBL] [Abstract][Full Text] [Related]
15. Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes. Reusch JE; Gadsby R Diabetes Technol Ther; 2003; 5(4):685-93. PubMed ID: 14511423 [TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes mellitus: prevention of macrovascular complications. Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994 [TBL] [Abstract][Full Text] [Related]
18. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Blonde L Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303 [TBL] [Abstract][Full Text] [Related]
19. Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes. Teleb M; Popp Switzer M; Elhanafi S; Elfar A; San Juan ZT Curr Cardiol Rep; 2016 Mar; 18(3):29. PubMed ID: 26886228 [TBL] [Abstract][Full Text] [Related]
20. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes]. Hemmingsen B; Lund SS; Vaag A Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]